Search
Phloroglucinol
go.drugbank.com/drugs/DB12944InvestigationalPhloroglucinol has been used in trials studying the diagnostic of Colonoscopy.
Categories: Compounds used in a research, industrial, or household settingZongertinib
go.drugbank.com/drugs/DB18762ApprovedInvestigational[L53873,A274363] On August 8, 2025, the US FDA granted accelerated approval to zongertinib for the treatment of advanced forms of non-small cell lung cancer (NSCLC) with HER2 tyrosine kinase domain
AP1081
go.drugbank.com/drugs/DB05233ExperimentalA transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Reposal
go.drugbank.com/drugs/DB13805ExperimentalReposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.
DDP-200
go.drugbank.com/drugs/DB05919ExperimentalDDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia
Drinabant
go.drugbank.com/drugs/DB05750InvestigationalAVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.
Daledalin
go.drugbank.com/drugs/DB09189ExperimentalIt has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
WIN 55212-2
go.drugbank.com/drugs/DB13950ExperimentalWIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical … It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling.
ICA-105665
go.drugbank.com/drugs/DB06089InvestigationalIn addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. … It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy.
GI-5005
go.drugbank.com/drugs/DB05942InvestigationalTarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.